Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients

CompletedOBSERVATIONAL
Enrollment

278

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

November 30, 2017

Study Completion Date

July 25, 2022

Conditions
Multiple Myeloma
Interventions
DIAGNOSTIC_TEST

Gene Expression Profiling

SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.

Trial Locations (1)

10125

University of Turin, Turin

All Listed Sponsors
lead

Mario Boccadoro

OTHER

NCT03409692 - Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients | Biotech Hunter | Biotech Hunter